227 related articles for article (PubMed ID: 9342579)
21. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
[TBL] [Abstract][Full Text] [Related]
22. Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
Fridman KU; Elmfeldt D; Wysocki M; Friberg PR; Andersson OK
Blood Press; 2002; 11(4):244-52. PubMed ID: 12361194
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
27. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.
Balavoine F; Azizi M; Bergerot D; De Mota N; Patouret R; Roques BP; Llorens-Cortes C
Clin Pharmacokinet; 2014 Apr; 53(4):385-95. PubMed ID: 24337978
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens; 2001 Dec; 19(12):2241-50. PubMed ID: 11725169
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Schuehly U; Ayalasomayajula S; Buchbjerg J; Pal P; Golor G; Prescott MF; Sunkara G; Hinder M; Langenickel TH
Eur J Clin Pharmacol; 2018 Sep; 74(9):1121-1130. PubMed ID: 29974143
[TBL] [Abstract][Full Text] [Related]
30. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan.
Daneshtalab N; Lewanczuk RZ; Russell A; Jamali F
J Clin Pharmacol; 2004 Mar; 44(3):245-52. PubMed ID: 14973301
[TBL] [Abstract][Full Text] [Related]
31. Valsartan/hydrochlorothiazide.
Langtry HD; McClellan KJ
Drugs; 1999 May; 57(5):751-5; discussion 756-8. PubMed ID: 10353300
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose.
Waldmeier F; Flesch G; Müller P; Winkler T; Kriemler HP; Bühlmayer P; De Gasparo M
Xenobiotica; 1997 Jan; 27(1):59-71. PubMed ID: 9041679
[TBL] [Abstract][Full Text] [Related]
34. [Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
Vaïsse B; Ghobrial H; Vaur L; Poncelet P; Asmar R; Herpin D; Mallion JM
Arch Mal Coeur Vaiss; 2001 Aug; 94(8):907-12. PubMed ID: 11575229
[TBL] [Abstract][Full Text] [Related]
35. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
[TBL] [Abstract][Full Text] [Related]
36. Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers.
Gossmann J; Burkhardt R; Harder S; Lenz T; Sedlmeyer A; Klinkhardt U; Haak T; Geiger H; Scheuermann EH
Clin Pharmacol Ther; 2000 Nov; 68(5):501-9. PubMed ID: 11103753
[TBL] [Abstract][Full Text] [Related]
37. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
Plum J; Bünten B; Németh R; Grabensee B
J Am Soc Nephrol; 1998 Dec; 9(12):2223-34. PubMed ID: 9848776
[TBL] [Abstract][Full Text] [Related]
38. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
[TBL] [Abstract][Full Text] [Related]
39. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
40. Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects.
Lottermoser K; Hertfelder HJ; Gohlke P; Vetter H; Düsing R
Clin Exp Hypertens; 2004 Jan; 26(1):13-26. PubMed ID: 15000294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
